Evidence map›Paper›PMID 36531260›Full record

ArticleF1000Research2022

Growth kinetics of multiple

Erizka Rivani, Pepy Dwi Endraswari, Agung Dwi Wahyu Widodo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. A Clinically Silent Resistance Phenotype That PromotesbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Novel Coumarins Derivatives for A. baumannii Lung Infection Developed by High-Throughput Screening and Reinforcement Learning.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024
    Article
  4. Growth kinetics of multipleF1000Research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Erizka RivaniDepartment of Microbiology, Faculty of Medicine, Sriwijaya University, Palembang, South Sumatera, 30114, Indonesia.
Pepy Dwi EndraswariDepartment of Microbiology, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60115, Indonesia.
Agung Dwi Wahyu WidodoDepartment of Microbiology, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60115, Indonesia.
Airlangga University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAmikacinAmpicillinAnti-Bacterial AgentsCarbapenemsHumansKineticsMeropenemSulbactamAmikacinAmpicillinAnti-Bacterial AgentsCarbapenemsMeropenemSulbactamsultamicillinAcinetobacter baumanniiamikacinampicillin-sulbactamantibiotic combinationsmeropenemtime-kill

Identifiers

PMID36531260
PMCPMC9723411
OpenAlexW4284970333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.